FLGTFulgent Genetics, Inc.
$20.87-7.8% 1Y
$20.87
$13.7952 weeks$30.85
FLGT in its own filings
FLGT's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
158
Events found in the filings · across 665 filings · the record starts in 2016
- Hard flags
- 1
Hard flags
- Most recent filing
- Jul 30, 2026
Most recent filing · Form 10-Q
- Record starts
- Jul 7, 2016
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 6, 2026
- Delisting notice / listing-rule failurehistorical
- 2022-11-23
- SEC comment-letter activity22 occurrences
- 2024-02-08
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Fulgent Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 2, 2026On June 1, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company will present updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session based on the Company's full abstract entitled …Other event · Form 8-K
- May 21, 2026On May 21, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company's full abstract entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”, presenting interim data from the Company's …Other event · Form 8-K
- May 14, 2026On May 14, 2026 (the “Effective Date”), at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Fulgent Genetics, Inc. (the “Company”), the Company’s stockholders approved the Fulgent Genetics, Inc. 2026 Equity Incentive Plan (the “2026 Plan”)Director or officer change · Form 8-K
- May 1, 2026Fulgent Reports First Quarter 2026 Financial Results.Earnings release · press release
- Mar 17, 2026The disclosure set forth under.Material agreement entered · Form 8-K
- Feb 27, 2026Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Dec 22, 2025Purchase and Sale Agreement On December 20, 2025, Inform Diagnostics, Inc. (the “Buyer”), a wholly owned subsidiary of Fulgent Genetics, Inc. (the “Company”), entered into a Purchase and Sale Agreement (the “PSA”) with Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp. (the “Seller”), Dermatopathology …Material agreement entered · Form 8-K
- Nov 7, 2025Fulgent Reports Third Quarter 2025 Financial Results.Earnings release · press release
- Oct 20, 2025On October 20, 2025, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing preliminary clinical data from the ongoing phase 2 trial of FID-007 in combination with cetuximab in ≤ 2 nd line treatment in patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Diagnostics & Research
Ranks #14 of 21 by RyuScore